Time for the ethical management of COVID-19 vaccines. Issue 8 (August 2021)

• Record Type: Journal Article
• Authors: Binagwaho, Agnes; Mathewos, Kedest; Davis, Sheila
• Is Part Of: Lancet. Volume 9:Issue 8(2021)
• Page Start: e1169
• Page End: e1171
• Publication Date: 2021-08
• Subjects: World health -- Periodicals; 362.105
• DOI: 10.1016/S2214-109X(21)00180-7
• Languages: English
• ISSNs: 2214-109X

Abstract

Summary: The ethical distribution of life-saving medical and public health interventions to vulnerable groups has often been overlooked. Valuation of life linked to an individual's country of origin, the pharmaceutical industry's prioritisation of profit, the exploitation of vulnerable groups in clinical trials, and the resulting hesitancy towards drugs and vaccines have, among other factors, made the human right to health unattainable for many people. The COVID-19 pandemic presents itself as an opportunity to reverse this long-standing trajectory of unethical practices in global health. By ensuring the ethical inclusion of vulnerable groups in the vaccine development process and making a safe, effective vaccine accessible to all, pharmaceutical companies, governments, and international organisations can usher in a new era of global health that relies solely on ethical decision making.